How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?

Rheumatology Oxford Journal

Fecha de publicación: 22 February 2017

DOI: https://doi.org/10.1093/rheumatology/kex016

Autores: Anne Musters; Sander W Tas

Background: Ideally, clinical decisions are guided by the principles of evidence-based medicine, which usually requires external research evidence. Randomized controlled trials (RCTs) are regarded as the highest level of clinical evidence. However, in rare, severe and often life-threatening immune-mediated inflammatory diseases (IMIDs), it is often impossible to conduct RCTs.

SEGUIR LEYENDO